Oramed Pharmaceuticals Inc. (ORMP) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Oramed Pharmaceuticals Inc. is a biotechnology company focused on oral drug delivery technology, primarily developing an oral insulin capsule (ORMD-0801) for Type 2 diabetes. Following the failure of its Phase 3 trials in early 2023, the company has been conducting a strategic review and preparing a new Phase 3 protocol based on subpopulation data analysis. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.34M |
| Net Loss (Attributable to Stockholders) | $(19.62M) | $(3.22M) | $(8.87M) | $(7.81M) |
| Loss Per Share (Basic & Diluted) | $(0.48) | $(0.08) | $(0.22) | $(0.19) |
| Cash and Cash Equivalents | $42.10M | $5.47M | $42.10M | $5.47M |
| Short-Term Deposits | $42.74M | $95.28M | $42.74M | $95.28M |
| Total Current Assets | $142.77M | $162.58M | $142.77M | $162.58M |
| Total Current Liabilities | $5.27M | $53.21M | $5.27M | $53.21M |
| Working Capital | $137.50M | $109.37M | $137.50M | $109.37M |
| Short-Term Borrowings | $0 | $51.01M | $0 | $51.01M |
Note: All figures in millions unless otherwise noted. The Q3 2024 Net Loss includes a significant non-cash financial loss of approximately $15.42M related to the revaluation of Scilex investments.
Material Changes vs. Prior Period
- Revenue: No revenue was recognized in Q3 2024 or YTD 2024, compared to $1.34M in YTD 2023. The prior year revenue was related to a license agreement with HTIT that concluded in June 2023.
- Net Loss: Q3 2024 net loss widened significantly to $19.62M from $3.22M in Q3 2023. This was driven primarily by a $15.42M net financial loss due to the revaluation of investments in Scilex Holding Company. YTD 2024 net loss was $8.87M, slightly higher than YTD 2023 ($7.81M).
- Operating Expenses:
- R&D: Increased 134% in Q3 2024 ($2.24M) vs. Q3 2023 ($0.96M) due to preparations for a new Phase 3 clinical trial. YTD R&D decreased 33% ($4.86M vs. $7.21M) due to the termination of previous trials.
- G&A: Decreased 67% in Q3 2024 ($0.85M) vs. Q3 2023 ($2.60M) due to reversals of expenses following executive resignations.
- Liquidity: Cash and cash equivalents increased to $42.10M from $9.06M at year-end 2023. Short-term borrowings of $51.01M outstanding at Dec 31, 2023, were fully repaid during the period.
Guidance, Outlook, and Material Events
- Scilex Transaction & Refinancing: The company holds a Tranche A Note and warrants from Scilex. In October 2024 (subsequent event), Oramed participated in a refinancing where $25M of the Tranche A Note was exchanged for a new Tranche B Note and warrants. Additionally, Oramed acquired a 50% interest in royalty receivables from Scilex products in exchange for $2.5M of the Tranche A Note principal.
- Joint Venture: In January 2024, Oramed entered a Joint Venture (JV) agreement with Hefei Tianhui Biotech (HTIT) to develop and commercialize oral insulin. The JV is 50/50 owned, with Oramed contributing IP and cash. Final agreements are pending.
- Stock Repurchase: In June 2024, the board authorized a $20M buyback program. During Q3 2024, the company repurchased and retired 539,452 shares for approximately $1.29M at an average price of $2.40/share. Approximately $7.98M remains available under the program.
- Tax Expense: The company recognized $2.77M in tax expenses YTD 2024, anticipating taxable income from the Scilex transaction to utilize tax loss carryforwards.
- Liquidity Outlook: Management believes current cash resources are sufficient to fund operations for at least the next 12 months.
Investor Verification Checklist
- Scilex Investment Valuation: Verify the fair value assumptions and credit risk of the remaining Tranche A Note and the new Tranche B Note, as these assets significantly impact the balance sheet and P&L volatility.
- Phase 3 Trial Status: Confirm the timeline and enrollment progress of the new Phase 3 oral insulin trial (ORA-D-013-3) submitted to the FDA.
- JV Agreement Finalization: Monitor the execution of the definitive agreements required to consummate the HTIT Joint Venture.
- Capital Requirements: Assess the runway of the $84.8M in liquid assets (cash + short-term deposits) against the projected costs of the new clinical trial and general operations.
- Stock Buyback Execution: Track the remaining $7.98M authorization and the company's commitment to returning capital versus funding R&D.